VectivBio Holding AG (Nasdaq: VECT)

https://www.vectivbio.com

VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD). VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (“CoA”). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidimias. *

	Start	2019-05-27 established (s-off)
	Group	Ironwood (Group)
	Predecessor	Therachon Holding AG
	Industry	apraglutide
	Person	Santarelli, Luca (VectivBio 202001– CEO before Therachon CEO + Roche 201110 Global Head Neuroscience Translational Area)
	Person 2	D’Augusta, Claudia (VectivBio 202203 CFO formerly TiGenix 201204 CFO)

	Region	Basel BS
	Country	Switzerland
	Street	36 Aeschenvorstadt
	City	4051 Basel BS
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2022-12-31)
	Currency	USD
	Annual sales	27,341,000 (revenue from customers, consolidated (2022) 2022-12-31)
	Profit	-93,735,000 (2022-12-31)
	Cash	221,416,000 (2022-12-31)

		* Document for »About Section«: VectivBio Holding AG. (3/30/22). "Press Release: VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts". Basel.

		Record changed: 2024-01-13

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Ironwood (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)